TEVETEN HCT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Teveten Hct, and when can generic versions of Teveten Hct launch?
Teveten Hct is a drug marketed by Abbvie and is included in one NDA.
The generic ingredient in TEVETEN HCT is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TEVETEN HCT?
- What are the global sales for TEVETEN HCT?
- What is Average Wholesale Price for TEVETEN HCT?
Summary for TEVETEN HCT
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 3 |
Patent Applications: | 8 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in TEVETEN HCT? | TEVETEN HCT excipients list |
DailyMed Link: | TEVETEN HCT at DailyMed |
![TEVETEN HCT drug patent expirations Drug patent expirations by year for TEVETEN HCT](/p/graph/s/t/TEVETEN_HCT-patent-expirations.png)
Recent Clinical Trials for TEVETEN HCT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Abbott | Phase 3 |
author! et al. BV | Phase 3 |
Synexus | Phase 3 |
US Patents and Regulatory Information for TEVETEN HCT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TEVETEN HCT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-002 | Nov 1, 2001 | ⤷ Sign Up | ⤷ Sign Up |
Abbvie | TEVETEN HCT | eprosartan mesylate; hydrochlorothiazide | TABLET;ORAL | 021268-001 | Nov 1, 2001 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TEVETEN HCT
See the table below for patents covering TEVETEN HCT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Norway | 902633 | ⤷ Sign Up | |
Poland | 290122 | ⤷ Sign Up | |
Slovakia | 13594 | IMIDAZOLYL-ALKENOIC ACIDS, A METHOD OF ITS MANUFACTURING, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE SUBSTANCES AND ITS APPLICATION | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TEVETEN HCT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0565634 | 91234 | Luxembourg | ⤷ Sign Up | 91234, EXPIRES: 20161213 |
0403159 | C300006 | Netherlands | ⤷ Sign Up | PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417 |
0403159 | 14/2000 | Austria | ⤷ Sign Up | PRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |